Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

Results Reported From Three NCI-Sponsored Clinical Trials

SOUTH SAN FRANCISCO, CA June 28, 2007 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced results from the analyses of three Phase II clinical trials of ispinesib administered as monotherapy, one in patients with hepatocellular cancer, one in patients with melanoma, and one in patients with hormone-refractory prostate cancer. Ispinesib is a novel small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division. Ispinesib has arisen from a broad strategic collaboration between Cytokinetics and GlaxoSmithKline (GSK) to discover, develop and commercialize novel small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. All three clinical trials were sponsored by the National Cancer Institute (NCI).

A Phase II clinical trial designed to evaluate the safety and efficacy of ispinesib in the treatment of patients with locally advanced, recurrent or metastatic hepatocellular cancer was recently completed. In Stage 1 of this two-stage clinical trial, 15 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. This trial was designed to require at least 1 confirmed partial or complete response out of 15 evaluable patients in Stage 1 in order to proceed to Stage 2. The best overall response was stable disease seen in 7 of the 15 patients treated. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the second stage and therefore recruitment to Stage 2 was not opened. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscript is being prepared.

A Phase
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:4/17/2015)... Apr. 17, 2015 Research and Markets ... "ADME-Toxicology Testing - Global Strategic Business Report" ... the worldwide markets for ADME-Toxicology Testing in US$ Million ... and ADME Testing. The report provides separate ... , Japan , Europe ...
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/vrd3bd/mammography ) ... - Global Strategic Business Report" report to their ... for Mammography Equipment in US$ Thousands by the following ... The report provides separate comprehensive analytics for the US, ... , Europe , Asia-Pacific ...
(Date:4/17/2015)... -- Today, the Pharmaceutical Research and Manufacturers of ... companies as "We Work For Health Champions" for ... service. Established in 2009, the We ... the biopharmaceutical industry to honor employees who have ... also shown an outstanding commitment to their communities ...
Breaking Medicine Technology:ADME-Toxicology Testing (In-Vivo, & In-Vitro) Market - Global Strategic Business Report 2015: Pharma Industry Renews Focus on Cost Optimization 2Mammography Equipment (Analog & Digital) Market 2015-2020 - Global Strategic Business Report: Breast Imaging Screening Programs Push Sales 2PhRMA Applauds 2015 We Work For Health Champion Award Winners 2PhRMA Applauds 2015 We Work For Health Champion Award Winners 3
... Texas , Feb. 3 Lexicon Pharmaceuticals, Inc. ... and developing breakthrough treatments for human disease, announced today that ... officer, will present at the 2010 BIO CEO & Investor Conference ... at 9:30 a.m., Eastern Time . The conference is ...
... , PITTSBURGH , Feb. 3 An ... work together to fight cancer.  Now, drug response markers such ... help to determine individual cancer treatment plans when using various ... Therapeutics, Inc., a life sciences company in Pittsburgh, Pennsylvania ...
Cached Medicine Technology:Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference 2Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference 3Patients, Physicians Rely on ChemoFx(R) to Support Their Cancer Treatment Decisions 2Patients, Physicians Rely on ChemoFx(R) to Support Their Cancer Treatment Decisions 3
(Date:4/17/2015)... WA (PRWEB) April 17, 2015 ERGO-Pedic ... cushions is introducing two new products to help a ... low back pain relief are the second most common ... our first product, designed specifically to help relieve sitting ... Comfort Cushion, and thousands of happy customers later, we ...
(Date:4/17/2015)... April 17, 2015 Alcohol and Violence ... (NCADD) notes that drinking and driving has been the ... the same time, the link between alcohol and crime ... abuse and violence and sexual assault, and their relationship ... the NCADD, 5.3 million adults in America were drinking ...
(Date:4/17/2015)... “We have seen healing, a lot of healing, ... said Chaplain Shawn Kafader of Friendship Village. “People have ... anything to contribute have created beautiful pieces of art.” For ... therapy program that was launched to benefit residents of the ... of the Art Institute in Chicago, worked as an intern ...
(Date:4/17/2015)... In Defense of Christians (IDC) Executive Director ... April 15th, the European Parliament joined its voice with ... Armenian Genocide, “paying tribute, on the eve of the ... Armenian victims who perished in the Ottoman Empire.” ... this timely and needed recognition of a tragic episode ...
(Date:4/17/2015)... 17, 2015 Representatives Jim Himes (D-CT) ... Treatment Act HR 1849 in congress on April 16, ... treatment for patients with the genetic disease. , ... would be the first to create a federally led ... of hereditary hemorrhagic telangiectasia. This would effectively prevent premature ...
Breaking Medicine News(10 mins):Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3Health News:Healing At Friendship Village Due To Art Therapy 2Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3Health News:House Representatives Introduce Bill to Fight Genetic Disease 2
... Expert Addresses Impact of Technology on Health; Fitness Expert ... Denise Austin Offers Nightly Wellness Tips, MORRIS PLAINS, N.J., ... reach for your cell phone or your gym bag? A new ... Americans are busier than ever before, often at the expense of,their ...
... MIAMI, April 24 Physicians Healthcare,Management Group, Inc. ... organizations (HMOs) in partnership with physicians,today announced that ... signed an agreement with Advantica EyeCare to provide,comprehensive ... be launched in,the latter half of 2008., ...
... announced that it will release first quarter 2008,financial results on Thursday, May ... The Company will host a conference call to discuss the first quarter,2008 ... First Quarter 2008 Earnings Conference Call, ... Thursday, May 1, 2008 at 5:00 p.m. Eastern Time, Dial-in: ...
... Best Gifts to Receive This Season are Those That Give Back and ... the Fight Against AIDS ... off,the Mother,s Day festivities a few weeks early at the INSPI(RED) Mothers,Brunch ... by Helena Christensen, Liya Kebede, Mya, and other (RED) supporters,to celebrate motherhood ...
... Lauren Center for Cancer Care and ... Prevention Are the First to Be Certified, NEW ... today announced that representatives from the Leukemia,& Lymphoma Society and ... the first to be certified and representatives from,the Cleveland Clinic ...
... Was Served, -, LOS ANGELES, April 23 ... against Yolanda McGriff, a Los Angeles-,based healthcare worker who ... a low-income, disabled veteran. McGriff was arrested for,trespass-related violations ... employer, a man who lived in what used to ...
Cached Medicine News:Health News:Wired, Working Americans Let Nighttime Health Routines Slide 2Health News:Wired, Working Americans Let Nighttime Health Routines Slide 3Health News:Wired, Working Americans Let Nighttime Health Routines Slide 4Health News:Phyhealth Signs Agreement with Advantica EyeCare to Provide Vision Services for Pilot HMO 2Health News:Get INSPI(RED) This Mother's Day 2Health News:Get INSPI(RED) This Mother's Day 3Health News:Get INSPI(RED) This Mother's Day 4Health News:Harold P. Freeman Patient Navigation Institute Completes First Trainings and Certifications 2Health News:Harold P. Freeman Patient Navigation Institute Completes First Trainings and Certifications 3Health News:Harold P. Freeman Patient Navigation Institute Completes First Trainings and Certifications 4Health News:Harold P. Freeman Patient Navigation Institute Completes First Trainings and Certifications 5Health News:Harold P. Freeman Patient Navigation Institute Completes First Trainings and Certifications 6Health News:Case Dropped Against Healthcare Worker Who Was Arrested While Providing Care to an Elderly, Disabled Man in Los Angeles Home 2
... C.B.S.SCIENTIFIC offers four different Series ... EPS-3000-II, the EPS-4000-II, and the EPS-6000-II. ... voltage, constant current, and constant power ... a powerful 300 milliamps maximum current/300 ...
... The PowerPac Basic power supply, ... output of 10-300 V, 4-400 ... unit contains a built-in switch ... with the appropriate power cord. ...
... Granular, free-flowing powder EEO (-m r ): 0.05 ... Remelt Point (1.5%): 88.0 1.5C Gel Strength ... 2 Gel Strength (1.5%): greater than or ... than or equal to 7% Turbidity (1.5%): less ...
... (Cl) ≤ 5000 mg/kg sulfate (SO 4 ) ≤ ... ≤ 5 mg/kg Co ≤ 5 mg/kg Cr ≤ ... mg/kg K ≤ 50 mg/kg Mg ≤ 5 mg/kg ... ≤ 5 mg/kg Pb ≤ 5 mg/kg Zn ≤ ...
Medicine Products: